Modeling dyskinesia in animal models of Parkinson disease

Experimental Neurology

Volumn 256, Issue , 2014, Pages 105-116

  Morin, Nicolas ^a,b   Jourdain, Vincent A ^a,b   Di Paolo, Thérèse ^a,b  

^a LAVAL UNIVERSITY   (Canada)

^b UNIVERSITÉ LAVAL   (Canada)

Author keywords

6 OHDA; Abnormal involuntary movements; Animal models; L DOPA; L DOPA induced dyskinesia; Motor complications; MPTP; Parkinson disease; Primate; Rodent

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; AMANTADINE; DOPAMINE; LEVODOPA; MAVOGLURANT; OXIDOPAMINE; SARIZOTAN;

ANIMAL BEHAVIOR; ANXIETY; BRAIN DAMAGE; BRAIN DEPTH STIMULATION; COGNITIVE DEFECT; DEPRESSION; DOPAMINERGIC NERVE CELL; DYSKINESIA; GASTROINTESTINAL DISEASE; HALLUCINATION; HUMAN; IDIOPATHIC DISEASE; IMPULSIVENESS; LONG TERM CARE; NONHUMAN; ORTHOSTATIC HYPOTENSION; PALLIDOTOMY; PARKINSON DISEASE; PRIORITY JOURNAL; REVIEW; RHESUS MONKEY; SEXUAL DYSFUNCTION; SLEEP DISORDER; SWEATING; SYMPTOM ASSESSMENT; THALAMOTOMY; URINARY TRACT DISEASE;

6-OHDA; ABNORMAL INVOLUNTARY MOVEMENTS; ANIMAL MODELS; L-DOPA; L-DOPA-INDUCED DYSKINESIA; MOTOR COMPLICATIONS; MPTP; PARKINSON DISEASE; PRIMATE; RODENT;

ANIMALS; ANTIPARKINSON AGENTS; DISEASE MODELS, ANIMAL; DYSKINESIA, DRUG-INDUCED; MPTP POISONING; OXIDOPAMINE; PARKINSON DISEASE, SECONDARY;

EID: 84900820438     PISSN: 00144886     EISSN: 10902430     Source Type: Journal    
DOI: 10.1016/j.expneurol.2013.01.024     Document Type: Review

References (244)

1. Ahlskog J., Muenter M. Frequency of levodopa-related dyskinesias and motor fluctuations as estimated from the cumulative literature. Mov. Disord. 2001, 16:448-458.
2. Albanese A., et al. Chronic administration of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine to monkeys: behavioural, morphological and biochemical correlates. Neuroscience 1993, 55:823-832.
3. Alvarez L., et al. Dorsal subthalamotomy for Parkinson's disease. Mov. Disord. 2001, 16:72-78.
4. Alvarez L., et al. Therapeutic efficacy of unilateral subthalamotomy in Parkinson's disease: results in 89 patients followed for up to 36months. J. Neurol. Neurosurg. Psychiatry 2009, 80:979-985.
5. Andersson M., et al. Striatal fosB expression is causally linked with l-DOPA-induced abnormal involuntary movements and the associated upregulation of striatal prodynorphin mRNA in a rat model of Parkinson's disease. Neurobiol. Dis. 1999, 6:461-474.
6. Aristieta A., et al. The role of the subthalamic nucleus in L-DOPA induced dyskinesia in 6-hydroxydopamine lesioned rats. PLoS One 2012, 7:e42652.
7. Aubert I., et al. Increased D1 dopamine receptor signaling in levodopa-induced dyskinesia. Ann. Neurol. 2005, 57:17-26.
8. Ballard P.A., et al. Permanent human parkinsonism due to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP): seven cases. Neurology 1985, 35:949-956.
9. Bara-Jimenez W., et al. Effects of serotonin 5-HT1A agonist in advanced Parkinson's disease. Mov. Dis. 2005, 20:932-936.
10. Barbeau A. High level levodopa therapy in several akinetic parkinsonian patients: twelve years later. Parkinson's Disease: Current Progress, Problems and Management 1980, 229-239. Elsevier, Amsterdam. J.K. Rinne, H. Klinger, G. Stamm (Eds.).
11. Barnes N.M., Sharp T. A review of central 5-HT receptors and their function. Neuropharmacology 1999, 38:1083-1152.
12. Baron M.S., Dalton W.B. Quetiapine as treatment for dopaminergic-induced dyskinesias in Parkinson's disease. Mov. Dis. 2003, 18:1208-1209.
13. Battista A.F., et al. Production of involuntary movements by L-dopa in monkeys with tegmental lesions. Exp. Neurol. 1971, 33:566-575.
14. Beaulieu J.M., et al. An Akt/beta-arrestin 2/PP2A signaling complex mediates dopaminergic neurotransmission and behavior. Cell 2005, 122:261-273.
15. Beaulieu J.M., et al. Paradoxical striatal cellular signaling responses to psychostimulants in hyperactive mice. J. Biol. Chem. 2006, 281:32072-32080.
16. Beaulieu J.M., et al. The Akt-GSK-3 signaling cascade in the actions of dopamine. Trends Pharmacol. Sci. 2007, 28:166-172.
17. Bedard P.J., et al. Chronic treatment with L-DOPA, but not bromocriptine induces dyskinesia in MPTP-parkinsonian monkeys. Correlation with [3H]spiperone binding. Brain Res. 1986, 379:294-299.
18. Berg D., et al. AFQ056 treatment of levodopa-induced dyskinesias: results of 2 randomized controlled trials. Mov. Disord. 2011, 26:1243-1250.
19. Bergman H., et al. The primate subthalamic nucleus. II. Neuronal activity in the MPTP model of parkinsonism. J. Neurophysiol. 1994, 72:507-520.
20. Berretta S., et al. Local release of GABAergic inhibition in the motor cortex induces immediate-early gene expression in indirect pathway neurons of the striatum. J. Neurosci. 1997, 17:4752-4763.
21. Bezard E., et al. Levetiracetam improves choreic levodopa-induced dyskinesia in the MPTP-treated macaque. Eur. J. Pharmacol. 2004, 485:159-164.
22. Bibbiani F., et al. Serotonin 5-HT1A agonist improves motor complications in rodent and primate parkinsonian models. Neurology 2001, 57:1829-1834.
23. Bido S., et al. Amantadine attenuates levodopa-induced dyskinesia in mice and rats preventing the accompanying rise in nigral GABA levels. J. Neurochem. 2011, 118:1043-1055.
24. Blanchet P.J., et al. Amantadine reduces levodopa-induced dyskinesias in parkinsonian monkeys. Mov. Disord. 1998, 13:798-802.
25. Blanchet P.J., et al. Differing effects of N-methyl-D-aspartate receptor subtype selective antagonists on dyskinesias in levodopa-treated 1-methyl-4-phenyl- tetrahydropyridine monkeys. J. Pharmacol. Exp. Ther. 1999, 290:1034-1040.
26. Blanchet P.J., et al. Relevance of the MPTP primate model in the study of dyskinesia priming mechanisms. Parkinsonism Relat. Disord. 2004, 10:297-304.
27. Bokobza B., et al. [3H]spiperone binding, dopamine and HVA concentrations in Parkinson's disease and supranuclear palsy. Eur. J. Pharmacol. 1984, 99:167-175.
28. Bonifati V., et al. Buspirone in levodopa-induced dyskinesias. Clin. Neuropharmacol. 1994, 17:73-82.
29. Bordia T., et al. Nicotine reduces antipsychotic-induced orofacial dyskinesia in rats. J. Pharmacol. Exp. Ther. 2012, 340:612-619.
30. Boyce S., et al. Induction of chorea and dystonia in parkinsonian primates. Mov. Disord. 1990, 5:3-7.
31. Boyce S., et al. Characterisation of dyskinesias induced by L-dopa in MPTP-treated squirrel monkeys. Psychopharmacology (Berl) 1990, 102:21-27.
32. Breese G.R., Traylor T.D. Effect of 6-hydroxydopamine on brain norepinephrine and dopamine evidence for selective degeneration of catecholamine neurons. J. Pharmacol. Exp. Ther. 1970, 174:413-420.
33. Brotchie J.M. Adjuncts to dopamine replacement: a pragmatic approach to reducing the problem of dyskinesia in Parkinson's disease. Mov. Disord. 1998, 13:871-876.
34. Brotchie J.M. CB1 cannabinoid receptor signalling in Parkinson's disease. Curr. Opin. Pharmacol. 2003, 3:54-61.
35. Burns R.S., et al. A primate model of parkinsonism: selective destruction of dopaminergic neurons in the pars compacta of the substantia nigra by N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. PNAS 1983, 80:4546-4550.
36. Calon F., Di Paolo T. Levodopa response motor complications - GABA receptors and preproenkephalin expression in human brain. Parkinsonism Relat. Disord. 2002, 8:449-454.
37. Calon F., et al. Alteration of glutamate receptors in the striatum of dyskinetic 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated monkeys following dopamine agonist treatment. Prog. Neuropsychopharmacol. Biol. Psychiatry 2002, 26:127-138.
38. Calon F., et al. Levodopa-induced motor complications are associated with alterations of glutamate receptors in Parkinson's disease. Neurobiol. Dis. 2003, 14:404-416.
39. Calon F., et al. Increased adenosine A2A receptors in the brain of Parkinson's disease patients with dyskinesias. Brain 2004, 127:1075-1084.
40. Carlsson M.L. Are the disparate pharmacological profiles of competitive and un-competitive NMDA antagonists due to different baseline activities of distinct glutamatergic pathways. J. Neural. Transm. Gen. Sect. 1993, 94:1-10. (Hypothesis).
41. Carta A.R., et al. Behavioral and biochemical correlates of the dyskinetic potential of dopaminergic agonists in the 6-OHDA lesioned rat. Synapse 2008, 62:524-533.
42. Cenci M.A., et al. L-DOPA-induced dyskinesia in the rat is associated with striatal overexpression of prodynorphin- and glutamic acid decarboxylase mRNA. Eur. J. Neurosci. 1998, 10:2694-2706.
43. Cenci M.A., et al. Animal models of neurological deficits: how relevant is the rat?. Nat. Rev. Neurosci. 2002, 3:574-579.
44. Cenci M.A., et al. Plastic effects of L-DOPA treatment in the basal ganglia and their relevance to the development of dyskinesia. Parkinsonism Relat. Disord. 2009, 15(Suppl. 3):S59-S63.
45. Chase T.N., Oh J.D. Striatal mechanisms and pathogenesis of parkinsonian signs and motor complications. Ann. Neurol. 2000, 47:S122-S129. (discussion S129-130).
46. Chaumette T., et al. Neurochemical plasticity in the enteric nervous system of a primate animal model of experimental Parkinsonism. Neurogastroenterol. Motil. 2009, 21:215-222.
47. Chesselet M.F. In vivo alpha-synuclein overexpression in rodents: a useful model of Parkinson's disease?. Exp. Neurol. 2008, 209:22-27.
48. Chong Z.Z., et al. Activating Akt and the brain's resources to drive cellular survival and prevent inflammatory injury. Histol. Histopathol. 2005, 20:299-315.
49. Clarke C.E., et al. Levodopa-induced dyskinesia and response fluctuations in primates rendered parkinsonian with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). J. Neurol. Sci. 1987, 78:273-280.
50. Cooper D.R., et al. L-Dopa methyl ester-a candidate for chronic systemic delivery of L-Dopa in Parkinson's disease. Clin. Neuropharmacol. 1984, 7:89-98.
51. Crossman A.R., et al. MPTP-induced parkinsonism in the monkey: neurochemical pathology, complications of treatment and pathophysiological mechanisms. Can. J. Neurol. Sci. 1987, 14:428-435.
52. Davis G.C., et al. Chronic Parkinsonism secondary to intravenous injection of meperidine analogues. Psychiatry Res. 1979, 1:249-254.
53. Dawson T.M., et al. Genetic animal models of Parkinson's disease. Neuron 2010, 66:646-661.
54. de Yebenes J.G., et al. Continuous intracerebroventricular infusion of dopamine and dopamine agonists through a totally implanted drug delivery system in animal models of Parkinson's disease. Mov. Disord. 1987, 2:143-158.
55. de Yebenes J.G., et al. Continuous intracerebroventricular infusion of dopamine and dopamine agonists through a totally implanted drug delivery system in animal models of Parkinson's disease. J. Neural. Transm. Suppl. 1988, 27:141-160.
56. Dekundy A., et al. Modulation of L-DOPA-induced abnormal involuntary movements by clinically tested compounds: further validation of the rat dyskinesia model. Behav. Brain Res. 2007, 179:76-89.
57. Deumens R., et al. Modeling Parkinson's disease in rats: an evaluation of 6-OHDA lesions of the nigrostriatal pathway. Exp. Neurol. 2002, 175:303-317.
58. Deuschl G., et al. A randomized trial of deep-brain stimulation for Parkinson's disease. N. Engl. J. Med. 2006, 355:896-908.
59. Di Chiara G., et al. Priming as a model of behavioural sensitization. Dev. Pharmacol. Ther. 1992, 18:223-227.
60. Di Monte D.A., et al. Relationship among nigrostriatal denervation, parkinsonism, and dyskinesias in the MPTP primate model. Mov. Disord. 2000, 15:459-466.
61. Ding Y., et al. Chronic 3,4-dihydroxyphenylalanine treatment induces dyskinesia in aphakia mice, a novel genetic model of Parkinson's disease. Neurobiol. Dis. 2007, 27:11-23.
62. Ding Y., et al. Enhanced striatal cholinergic neuronal activity mediates L-DOPA-induced dyskinesia in parkinsonian mice. Proc. Natl. Acad. Sci. U. S. A. 2011, 108:840-845.
63. Durif F., et al. Levodopa-induced dyskinesias are improved by fluoxetine. Neurology 1995, 45:1855-1858.
64. Duty S., Jenner P. Animal models of Parkinson's disease: a source of novel treatments and clues to the cause of the disease. Br. J. Pharmacol. 2011, 164:1357-1391.
65. Eskow K.L., et al. The partial 5-HT(1A) agonist buspirone reduces the expression and development of l-DOPA-induced dyskinesia in rats and improves l-DOPA efficacy. Pharmacol. Biochem. Behav. 2007, 87:306-314.
66. Evans A.H., et al. Punding in Parkinson's disease: its relation to the dopamine dysregulation syndrome. Mov. Disord. 2004, 19:397-405.
67. Evans A.H., et al. Dyskinetic patients show rebound worsening of affect after an acute L-dopa challenge. Parkinsonism Relat. Disord. 2012, 18:514-519.
68. Fahn S., et al. Levodopa and the progression of Parkinson's disease. N. Engl. J. Med. 2004, 351:2498-2508.
69. Falardeau P., et al. Behavioral and biochemical effect of chronic treatment with D-1 and/or D-2 dopamine agonists in MPTP monkeys. Eur. J. Pharmacol. 1988, 150:59-66.
70. Fasano A., et al. Treatment of motor and non-motor features of Parkinson's disease with deep brain stimulation. Lancet Neurol. 2012, 11:429-442.
71. Fenu S., et al. Adenosine A2A receptor antagonism potentiates L-DOPA-induced turning behaviour and c-fos expression in 6-hydroxydopamine-lesioned rats. Eur. J. Pharmacol. 1997, 321:143-147.
72. Fernandez H.H., Friedman J.H. Punding on L-dopa. Mov. Disord. 1999, 14:836-838.
73. Follett K.A., et al. Pallidal versus subthalamic deep-brain stimulation for Parkinson's disease. N. Engl. J. Med. 2010, 362:2077-2091.
74. Fox S.H., Brotchie J.M. The MPTP-lesioned non-human primate models of Parkinson's disease. Past, present, and future. Prog. Brain Res. 2010, 184:133-157.
75. Fox S.H., et al. The movement disorder society evidence-based medicine review update: treatments for the motor symptoms of Parkinson's disease. Mov. Dis. 2011, 26(Suppl. 3):S2-S41.
76. Fox S.H., et al. A critique of available scales and presentation of the non-human primate dyskinesia rating scale. Mov. Disord. 2012, 27:1373-1378.
77. Francardo V., et al. Impact of the lesion procedure on the profiles of motor impairment and molecular responsiveness to L-DOPA in the 6-hydroxydopamine mouse model of Parkinson's disease. Neurobiol. Dis. 2011, 42:327-340.
78. Gagnon C., et al. Effect of chronic treatment of MPTP monkeys with dopamine D-1 and/or D- 2 receptor agonists. Eur. J. Pharmacol. 1990, 178:115-120.
79. Garcia B.G., et al. Cortical regulation of striatal medium spiny neuron dendritic remodeling in parkinsonism: modulation of glutamate release reverses dopamine depletion-induced dendritic spine loss. Cereb. Cortex. 2010, 20:2423-2432.
80. Gilmour T.P., et al. The effects of chronic levodopa treatments on the neuronal firing properties of the subthalamic nucleus and substantia nigra reticulata in hemiparkinsonian rhesus monkeys. Exp. Neurol. 2011, 228:53-58.
81. Glinka Y., et al. Mechanism of 6-hydroxydopamine neurotoxicity. J. Neural. Transm. Suppl. 1997, 50:55-66.
82. Goetz C.G., et al. Drug holiday in the management of Parkinson disease. Clin. Neuropharmacol. 1982, 5:351-364.
83. Goetz C.G., et al. Sarizotan as a treatment for dyskinesias in Parkinson's disease: a double-blind placebo-controlled trial. Mov. Dis. 2007, 22:179-186.
84. Goetz C.G., et al. Placebo influences on dyskinesia in Parkinson's disease. Mov. Dis. 2008, 23:700-707.
85. Gomez-Mancilla B., Bedard P.J. Effect of nondopaminergic drugs on L-dopa-induced dyskinesias in MPTP-treated monkeys. Clin. Neuropharmacol. 1993, 16:418-427.
86. Graham W.C., et al. Differential effect of chronic dopaminergic treatment on dopamine D1 and D2 receptors in the monkey brain in MPTP-induced parkinsonism. Brain Res. 1993, 602:290-303.
87. Graybiel A.M., et al. Levodopa-induced dyskinesias and dopamine-dependent stereotypies: a new hypothesis. Trends Neurosci. 2000, 23:S71-S77.
88. Greengard P. The neurobiology of slow synaptic transmission. Science 2001, 294:1024-1030.
89. Grégoire L., et al. Prolonged kynurenine 3-hydroxylase inhibition reduces development of levodopa-induced dyskinesias in parkinsonian monkeys. Behav. Brain Res. 2008, 186:161-167.
90. Grégoire L., et al. Low doses of sarizotan reduce dyskinesias and maintain antiparkinsonian efficacy of L-Dopa in parkinsonian monkeys. Parkinsonism Relat. Disord. 2009, 15:445-452.
91. Grégoire L., et al. The acute antiparkinsonian and antidyskinetic effect of AFQ056, a novel metabotropic glutamate receptor type 5 antagonist, in L-Dopa-treated parkinsonian monkeys. Parkinsonism Relat. Disord. 2011, 17:270-276.
92. Grondin R., et al. Antiparkinsonian effect of a new selective adenosine A2A receptor antagonist in MPTP-treated monkeys. Neurology 1999, 52:1673-1677.
93. Gubellini P., et al. Chronic high-frequency stimulation of the subthalamic nucleus and L-DOPA treatment in experimental parkinsonism: effects on motor behaviour and striatal glutamate transmission. Eur. J. Neurosci. 2006, 24:1802-1814.
94. Guigoni C., et al. Levodopa-induced dyskinesia in MPTP-treated macaques is not dependent on the extent and pattern of nigrostrial lesioning. Eur. J. Neurosci. 2005, 22:283-287.
95. Guttman M., et al. Dopamine D2 receptor density remains constant in treated Parkinson's disease. Ann. Neurol. 1986, 19:487-492.
96. Hadj Tahar A., et al. Sustained cabergoline treatment reverses levodopa-induced dyskinesias in parkinsonian monkeys. Clin. Neuropharmacol. 2000, 23:195-202.
97. Hadj Tahar A., et al. Effect of a selective glutamate antagonist on L-dopa-induced dyskinesias in drug-naive parkinsonian monkeys. Neurobiol. Dis. 2004, 15:171-176.
98. Hariz M.I. Pallidotomy for Parkinson's disease. Textbook of Stereotactic and Functional Neurosurgery 2009, 1539-1548. Springer-Verlag, Berlin. A.M. Lozano, P.L. Gildenberg, R.R. Tasker (Eds.).
99. Heimer G., et al. Dopamine replacement therapy reverses abnormal synchronization of pallidal neurons in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine primate model of parkinsonism. J. Neurosci. 2002, 22:7850-7855.
100. Henry B., et al. Characterization of enhanced behavioral responses to L-DOPA following repeated administration in the 6-hydroxydopamine-lesioned rat model of Parkinson's disease. Exp. Neurol. 1998, 151:334-342.
101. Henry B., et al. Mu- and delta-opioid receptor antagonists reduce levodopa-induced dyskinesia in the MPTP-lesioned primate model of Parkinson's disease. Exp. Neurol. 2001, 171:139-146.
102. Hooper A.K., et al. Clinical cases where lesion therapy was chosen over deep brain stimulation. Stereotact. Funct. Neurosurg. 2008, 86:147-152.
103. Huot P., et al. Increased 5-HT2A receptors in the temporal cortex of parkinsonian patients with visual hallucinations. Mov. Disord. 2010, 25:1399-1408.
104. Huot P., et al. The serotonergic system in Parkinson's disease. Prog. Neurobiol. 2011, 95:163-212.
105. Hurley M.J., et al. D3 receptor expression within the basal ganglia is not affected by Parkinson's disease. Neurosci. Lett. 1996, 214:75-78.
106. Hutchison W., et al. Effects of apomorphine on globus pallidus neurons in parkinsonian patients. Ann. Neurol. 1997, 42:767-775.
107. Iravani M.M., et al. 3,4-methylenedioxymethamphetamine (ecstasy) inhibits dyskinesia expression and normalizes motor activity in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated primates. J. Neurosci. 2003, 23:9107-9115.
108. Iravani M.M., et al. Unilateral pallidotomy in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated common marmosets exhibiting levodopa-induced dyskinesia. Eur. J. Neurosci. 2005, 22:1305-1318.
109. Jacks B.R., et al. Effects of 6-hydroxydopamine on putative transmitter substances in the central nervous system. Eur. J. Pharmacol. 1972, 18:353-360.
110. Jenner P. The contribution of the MPTP-treated primate model to the development of new treatment strategies for Parkinson's disease. Parkinsonism Relat. Disord. 2003, 9:131-137.
111. Jenner P. The MPTP-treated primate as a model of motor complications in PD: primate model of motor complications. Neurology 2003, 61:S4-S11.
112. Jenner P. From the MPTP-treated primate to the treatment of motor complications in Parkinson's disease. Parkinsonism Relat. Dis. 2009, 15(Suppl. 4):S18-S23.
113. Jenner P., et al. 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced parkinsonism in the common marmoset. Neurosci. Lett. 1984, 50:85-90.
114. Johnston T.H., et al. Reduction of L-DOPA-induced dyskinesia by the selective metabotropic glutamate receptor 5 antagonist 3-[(2-methyl-1,3-thiazol-4-yl)ethynyl]pyridine in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned macaque model of Parkinson's disease. J. Pharmacol. Exp. Ther. 2010, 333:865-873.
115. Jourdain V.A., et al. Potentiation of response to low doses of levodopa in MPTP-injected monkeys by chemical unilateral subthalamotomy. J. Neurosurg. 2013, 118:180-191.
116. Kannari K., et al. Activation of 5-HT(1A) but not 5-HT(1B) receptors attenuates an increase in extracellular dopamine derived from exogenously administered L-DOPA in the striatum with nigrostriatal denervation. J. Neurochem. 2001, 76:1346-1353.
117. Katzenschlager R., et al. Fourteen-year final report of the randomized PDRG-UK trial comparing three initial treatments in PD. Neurology 2008, 71:474-480.
118. Klawans H.L., et al. Levodopa-induced dopamine receptor hypersensitivity. Trans. Am. Neurol. Assoc. 1977, 102:80-83.
119. Kleedorfer B., et al. Buspirone in the treatment of levodopa induced dyskinesias. J. Neurol. Neurosurg. Psychiatry 1991, 54:376-377.
120. Klockgether T., Turski L. Toward an understanding of the role of glutamate in experimental parkinsonism: agonist-sensitive sites in the basal ganglia. Ann. Neurol. 1993, 34:585-593.
121. Kobylecki C., et al. Calcium-permeable AMPA receptors are involved in the induction and expression of l-DOPA-induced dyskinesia in Parkinson's disease. J. Neurochem. 2010, 114:499-511.
122. Kobylecki C., et al. Synergistic antidyskinetic effects of topiramate and amantadine in animal models of Parkinson's disease. Mov. Dis. 2011, 26:2354-2363.
123. Konitsiotis S., Tsironis C. Levodopa-induced dyskinesia and rotational behavior in hemiparkinsonian rats: independent features or components of the same phenomenon?. Behav. Brain Res. 2006, 170:337-341.
124. Kunikowska G., Jenner P. 6-Hydroxydopamine-lesioning of the nigrostriatal pathway in rats alters basal ganglia mRNA for copper, zinc- and manganese-superoxide dismutase, but not glutathione peroxidase. Brain Res. 2001, 922:51-64.
125. Kuoppamäki M., et al. Beginning-of-dose and rebound worsening in MPTP-treated common marmosets treated with levodopa. Mov. Disord. 2002, 17:1312-1317.
126. Kuoppamäki M., et al. L-dopa dose and the duration and severity of dyskinesia in primed MPTP-treated primates. J. Neural. Transm. 2007, 114:1147-1153.
127. Lacombe E., et al. High-frequency stimulation of the subthalamic nucleus prolongs the increase in striatal dopamine induced by acute l-3,4-dihydroxyphenylalanine in dopaminergic denervated rats. Eur. J. Neurosci. 2007, 26:1670-1680.
128. Langston J.W., et al. Chronic Parkinsonism in humans due to a product of meperidine-analog synthesis. Science 1983, 219:979-980.
129. Langston J.W., et al. Selective nigral toxicity after systemic administration of 1-methyl-4-phenyl-1,2,5,6-tetrahydropyrine (MPTP) in the squirrel monkey. Brain Res. 1984, 292:390-394.
130. Lee T., et al. Receptor basis for dopaminergic supersensitivity in Parkinson's disease. Nature 1978, 273:59-61.
131. Lee J.I., et al. Internal pallidal neuronal activity during mild drug-related dyskinesias in Parkinson's disease: decreased firing rates and altered firing patterns. J. Neurophysiol. 2007, 97:2627-2641.
132. Levandis G., et al. Systemic administration of an mGluR5 antagonist, but not unilateral subthalamic lesion, counteracts l-DOPA-induced dyskinesias in a rodent model of Parkinson's disease. Neurobiol. Dis. 2008, 29:161-168.
133. Levy R., et al. Effects of apomorphine on subthalamic nucleus and globus pallidus internus neurons in patients with Parkinson's disease. J. Neurophysiol. 2001, 86:249-260.
134. Li X., et al. Enhanced striatal dopamine transmission and motor performance with LRRK2 overexpression in mice is eliminated by familial Parkinson's disease mutation G2019S. J. Neurosci. 2010, 30:1788-1797.
135. Lieu C.A., et al. Dyskinesias do not develop after chronic intermittent levodopa therapy in clinically hemiparkinsonian rhesus monkeys. Parkinsonism Relat. Disord. 2011, 17:34-39.
136. Linazasoro G., et al. Levodopa-induced dyskinesias in Parkinson disease are independent of the extent of striatal dopaminergic denervation: a pharmacological and SPECT study. Clin. Neuropharmacol. 2009, 32:326-329.
137. Lindgren H.S., et al. The "motor complication syndrome" in rats with 6-OHDA lesions treated chronically with L-DOPA: relation to dose and route of administration. Behav. Brain Res. 2007, 177:150-159.
138. Lindgren H.S., et al. Differential involvement of D1 and D2 dopamine receptors in L-DOPA-induced angiogenic activity in a rat model of Parkinson's disease. Neuropsychopharmacology 2009, 34:2477-2488.
139. Lundblad M., et al. Pharmacological validation of behavioural measures of akinesia and dyskinesia in a rat model of Parkinson's disease. Eur. J. Neurosci. 2002, 15:120-132.
140. Lundblad M., et al. A model of L-DOPA-induced dyskinesia in 6-hydroxydopamine lesioned mice: relation to motor and cellular parameters of nigrostriatal function. Neurobiol. Dis. 2004, 16:110-123.
141. Lundblad M., et al. Pharmacological validation of a mouse model of l-DOPA-induced dyskinesia. Exp. Neurol. 2005, 194:66-75.
142. Luquin M.R., et al. Levodopa-induced dyskinesias in Parkinson's disease: clinical and pharmacological classification. Mov. Dis. 1992, 7:117-124.
143. Luthman J., et al. Effects of d-amphetamine and methylphenidate on hyperactivity produced by neonatal 6-hydroxydopamine treatment. Psychopharmacology (Berl) 1989, 99:550-557.
144. Lyons K.E., Pahwa R. The impact and management of nonmotor symptoms of Parkinson's disease. Am. J. Manag. Care 2011, 17(Suppl. 12):S308-S314.
145. Marin C., et al. Bilateral subthalamic nucleus lesion reverses L-dopa-induced motor fluctuations and facilitates dyskinetic movements in hemiparkinsonian rats. Synapse 2004, 51:140-150.
146. Marin C., et al. The metabotropic glutamate receptor antagonist 2-methyl-6-(phenylethynyl) pyridine decreases striatal VGlut2 expression in association with an attenuation of L-DOPA-induced dyskinesias. Synapse 2011, 65:1080-1086.
147. Marsden C., et al. Nm Fluctuations of disability in Parkinson's disease - clinical aspects. Movement Disorders 1982, 96-122. Butterworths Scientific, London. C.D. Marsden, S. Fahn (Eds.).
148. Martin R.F., Bowden D.M. Primate Brain Maps: Structure of the Macaque Brain 2000, Elsevier Science B.V., Amsterdam, The Netherlands.
149. Mayeux R., et al. Reappraisal of temporary levodopa withdrawal (&"drug holiday&") in Parkinson's disease. N. Engl. J. Med. 1985, 313:724-728.
150. Mazzio E.A., et al. The role of oxidative stress, impaired glycolysis and mitochondrial respiratory redox failure in the cytotoxic effects of 6-hydroxydopamine in vitro. Brain Res. 2004, 1004:29-44.
151. McIntosh E.S. Perspective on the economic evaluation of deep brain stimulation. Front. Integr. Neurosci. 2011, 5:19.
152. Mela F., et al. Antagonism of metabotropic glutamate receptor type 5 attenuates l-DOPA-induced dyskinesia and its molecular and neurochemical correlates in a rat model of Parkinson's disease. J. Neurochem. 2007, 101:483-497.
153. Meltzer H.Y., et al. Serotonin receptors: their key role in drugs to treat schizophrenia. Prog. Neuropsychopharmacol. Biol. Psychiatry 2003, 27:1159-1172.
154. Merello M., et al. Prospective randomized 1-year follow-up comparison of bilateral subthalamotomy versus bilateral subthalamic stimulation and the combination of both in Parkinson's disease patients: a pilot study. Br. J. Neurosurg. 2008, 22:415-422.
155. Missale C., et al. Dopamine receptors: from structure to function. Physiol. Rev. 1998, 78:189-225.
156. Mitchell I.J., Carroll C.B. Reversal of parkinsonian symptoms in primates by antagonism of excitatory amino acid transmission: potential mechanisms of action. Neurosci. Biobehav. Rev. 1997, 21:469-475.
157. Mitchell I.J., et al. Reversal of parkinsonian symptoms by intrastriatal and systemic manipulations of excitatory amino acid and dopamine transmission in the bilateral 6-OHDA lesioned marmoset. Behav. Pharmacol. 1995, 6:492-507.
158. Mones R.J. Experimental Dyskinesias in Normal Rhesus Monkeys. Adv Neurol 1973, 665-669. Raven Press, New York. A. Barbeau, T.N. Chase, G.W. Paulson (Eds.).
159. Mones R.J., et al. Analysis of L-dopa induced dyskinesias in 51 patients with Parkinsonism. J. Neurol. Neurosurg. Psychiatry 1971, 34:668-673.
160. Morin N., et al. Effect of the metabotropic glutamate receptor type 5 antagonists MPEP and MTEP in parkinsonian monkeys. Neuropharmacology 2010, 58:981-986.
161. Morin N., et al. MPEP, an mGlu5 receptor antagonist, reduces the development of l-DOPA-induced motor complications in de novo parkinsonian monkeys: Biochemical correlates. Neuropharmacology 2013, 66:355-364.
162. Morissette M., et al. Associative and limbic regions of monkey striatum express high levels of dopamine D3 receptors: effects of MPTP and dopamine agonist replacement therapies. Suppl. Eur. J. Neurosci. 1998, 10:2565-2573.
163. Morissette M., et al. Striatal Akt/GSK3 signaling pathway in the development of L-Dopa-induced dyskinesias in MPTP monkeys. Prog. Neuropsychopharmacol. Biol. Psychiatry 2010, 34:446-454.
164. Munoz A., et al. Combined 5-HT1A and 5-HT1B receptor agonists for the treatment of L-DOPA-induced dyskinesia. Brain 2008, 131:3380-3394.
165. Nadjar A., et al. Priming for l-dopa-induced dyskinesia in Parkinson's disease: a feature inherent to the treatment or the disease?. Prog. Neurobiol. 2009, 87:1-9.
166. Narabayashi H., Kubota K. Reconsideration of ventrolateral thalamotomy for hyperkinesis. Prog. Brain Res. 1966, 21:339-349.
167. Navailles S., et al. High-Frequency Stimulation of the Subthalamic Nucleus and L-3,4-Dihydroxyphenylalanine Inhibit In Vivo Serotonin Release in the Prefrontal Cortex and Hippocampus in a Rat Model of Parkinson's Disease. J. Neurosci. 2010, 30:2356-2364.
168. Nicholas A.P. Levodopa-induced hyperactivity in mice treated with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Mov. Dis. 2007, 22:99-104.
169. Nutt J.G. Levodopa-induced dyskinesia: review, observations, and speculations. Neurology 1990, 40:340-345.
170. Oh J.D., et al. Quetiapine attenuates levodopa-induced motor complications in rodent and primate parkinsonian models. Exp. Neurol. 2002, 177:557-564.
171. Olanow C.W. The scientific basis for the current treatment of Parkinson's disease. Ann. Rev. Med. 2004, 55:41-60.
172. Olanow C.W., Koller W.C. An algorithm (decision tree) for the management of Parkinson's disease: treatment guidelines. American Academy of Neurology. Neurology 1998, 50:S1-S57. (Review).
173. Olanow C.W., et al. Multicenter, open-label, trial of sarizotan in Parkinson disease patients with levodopa-induced dyskinesias (the SPLENDID Study). Clin. Neuropharmacol. 2004, 27:58-62.
174. Olanow C.W., et al. The scientific and clinical basis for the treatment of Parkinson disease (2009). Neurology 2009, 72:S1-S136.
175. Ouattara B., et al. Implication of NMDA Receptors in the Antidyskinetic Activity of Cabergoline, CI-1041, and Ro 61-8048 in MPTP Monkeys with Levodopa-induced Dyskinesias. J. Mol. Neurosci. 2009, 38:128-142.
176. Ouattara B., et al. Effect of L-Dopa on metabotropic glutamate receptor 5 in the brain of parkinsonian monkeys. J. Neurochem. 2010, 113:715-724.
177. Ouattara B., et al. Changes of AMPA receptors in MPTP monkeys with levodopa-induced dyskinesias. Neuroscience 2010, 167:1160-1167.
178. Ouattara B., et al. Metabotropic glutamate receptor type 5 in levodopa-induced motor complications. Neurobiol. Aging 2011, 32:1286-1295.
179. Oueslati A., et al. High-frequency stimulation of the subthalamic nucleus potentiates L-DOPA-induced neurochemical changes in the striatum in a rat model of Parkinson's disease. J. Neurosci. 2007, 27:2377-2386.
180. Page R.D., et al. Thalamotomy for the alleviation of levodopa-induced dyskinesia: experimental studies in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated parkinsonian monkey. Neuroscience 1993, 55:147-165.
181. Pahwa R., Lyons K.E. Levodopa-related wearing-off in Parkinson's disease: identification and management. Curr. Med. Res. Opin. 2009, 25:841-849.
182. Paille V., et al. Rat model of Parkinson's disease with bilateral motor abnormalities, reversible with levodopa, and dyskinesias. Mov. Dis. 2007, 22:533-539.
183. Papa S.M., et al. Motor fluctuations in levodopa treated parkinsonian rats: relation to lesion extent and treatment duration. Brain Res. 1994, 662:69-74.
184. Parent A., Hazrati L.N. Functional anatomy of the basal ganglia. II. The place of subthalamic nucleus and external pallidum in basal ganglia circuitry. Brain Res. Rev. 1995, 20:128-154.
185. Parent A., et al. A re-evaluation of the current model of the basal ganglia. Parkinsonism Relat. Disord. 2001, 7:193-198.
186. Parkinson Study Group Long-term effect of initiating pramipexole vs levodopa in early Parkinson disease. Arch. Neurol. 2009, 66:563-570.
187. Paxinos G., Watson C. The Rat Brain in Stereotaxic Coordinates 2007, Academic Press, London, UK.
188. Pearce R.K., et al. Chronic L-DOPA administration induces dyskinesias in the 1-methyl-4- phenyl-1,2,3,6-tetrahydropyridine-treated common marmoset (Callithrix Jacchus). Mov. Disord. 1995, 10:731-740.
189. Pearce R.K., et al. L-dopa induces dyskinesia in normal monkeys: behavioural and pharmacokinetic observations. Psychopharmacology (Berl) 2001, 156:402-409.
190. Pelech S.L., Charest D.L. MAP kinase-dependent pathways in cell cycle control. Prog. Cell Cycle Res. 1995, 1:33-52.
191. Périer C., et al. Effect of subthalamic nucleus or entopeduncular nucleus lesion on levodopa-induced neurochemical changes within the basal ganglia and on levodopa-induced motor alterations in 6-hydroxydopamine-lesioned rats. J. Neurochem. 2003, 86:1328-1337.
192. Pirker W., et al. Coadministration of (-)-OSU6162 with l-DOPA normalizes preproenkephalin mRNA expression in the sensorimotor striatum of primates with unilateral 6-OHDA lesions. Exp. Neurol. 2001, 169:122-134.
193. Poirier L.J. Experimental and histological study of midbrain dyskinesias. J. Neurophysiol. 1960, 23:534-551.
194. Quik M., et al. Expression of D(3) receptor messenger RNA and binding sites in monkey striatum and substantia nigra after nigrostriatal degeneration: effect of levodopa treatment. Neuroscience 2000, 98:263-273.
195. Quik M., et al. Increases in striatal preproenkephalin gene expression are associated with nigrostriatal damage but not L-DOPA-induced dyskinesias in the squirrel monkey. Neuroscience 2002, 113:213-220.
196. Quik M., et al. Nicotine reduces levodopa-induced dyskinesias in lesioned monkeys. Ann. Neurol. 2007, 62:588-596.
197. Quintana A., et al. Effects of L-DOPA and STN-HFS dyskinesiogenic treatments on NR2B regulation in basal ganglia in the rat model of Parkinson's disease. Neurobiol. Dis. 2012, 48:379-390.
198. Rajput A.H., et al. Is levodopa toxic to human substantia nigra?. Mov. Disord. 1997, 12:634-638.
199. Rajput A.H., et al. Course in Parkinson disease subtypes: A 39-year clinicopathologic study. Neurology 2009, 73:206-212.
200. Redmond D.E. Behavioral Assessment in the African Green Monkey after MPTP Administration. Animal Models of Movement Disorders 2012, 401-435. Springer, New York. E.L. Lane, S.B. Dunnett (Eds.).
201. Richard I.H., et al. Mood fluctuations in Parkinson's disease: a pilot study comparing the effects of intravenous and oral levodopa administration. Neuropsychiatr. Dis. Treat. 2005, 1:261-268.
202. Rylander D., et al. Pharmacological modulation of glutamate transmission in a rat model of L-DOPA-induced dyskinesia: effects on motor behavior and striatal nuclear signaling. J. Pharmacol. Exp. Ther. 2009, 330:227-235.
203. Rylander D., et al. A mGluR5 antagonist under clinical development improves L-DOPA-induced dyskinesia in parkinsonian rats and monkeys. Neurobiol. Dis. 2010, 39:352-361.
204. Rylander D., et al. Maladaptive plasticity of serotonin axon terminals in levodopa-induced dyskinesia. Ann. Neurol. 2010, 68:619-628.
205. Ryoo H.L., et al. Dopamine D3 receptor is decreased and D2 receptor is elevated in the striatum of Parkinson's disease. Mov. Disord. 1998, 13:788-797.
206. Sachs C., Jonsson G. Mechanisms of action of 6-hydroxydopamine. Biochem. Pharmacol. 1975, 24:1-8.
207. Salinas P.C. Wnt factors in axonal remodelling and synaptogenesis. Biochem. Soc. Symp. 1999, 65:101-109.
208. Samadi P., et al. Docosahexaenoic acid reduces levodopa-induced dyskinesias in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine monkeys. Ann. Neurol. 2006, 59:282-288.
209. Samadi P., et al. Functional neurochemistry of the basal ganglia. Handbook of Clinical Neurology 2007, 83:19-66. P.J. Vinken, G.W. (Eds.).
210. Samadi P., et al. mGluR5 metabotropic glutamate receptors and dyskinesias in MPTP monkeys. Neurobiol. Aging 2008, 29:1040-1051.
211. Santini E., et al. Critical involvement of cAMP/DARPP-32 and extracellular signal-regulated protein kinase signaling in L-DOPA-induced dyskinesia. J. Neurosci. 2007, 27:6995-7005.
212. Santini E., et al. Distinct changes in cAMP and extracellular signal-regulated protein kinase signalling in L-DOPA-induced dyskinesia. PLoS One 2010, 5:e12322.
213. Sassin J.F. Drug-induced Dyskinesia in Monkeys. Adv Neurol 1975, 47-54. Raven Press, New York. B.S. Meldrum, C.D. Marsden (Eds.).
214. Schneider J.S. Levodopa-induced dyskinesias in parkinsonian monkeys: relationship to extent of nigrostriatal damage. Pharmacol. Biochem. Behav. 1989, 34:193-196.
215. Schneider J.S. Chronic exposure to low doses of MPTP. II. Neurochemical and pathological consequences in cognitively-impaired, motor asymptomatic monkeys. Brain Res. 1990, 534:25-36.
216. Schrag A., et al. Young-onset Parkinson's disease revisited-clinical features, natural history, and mortality. Mov. Disord. 1998, 13:885-894.
217. Schwarting R.K., Huston J.P. Unilateral 6-hydroxydopamine lesions of meso-striatal dopamine neurons and their physiological sequelae. Prog. Neurobiol. 1996, 49:215-266.
218. Sedelis M., et al. MPTP susceptibility in the mouse: behavioral, neurochemical, and histological analysis of gender and strain differences. Behav. Genet. 2000, 30:171-182.
219. Shaw P.C., et al. Isolation and chromosomal mapping of human glycogen synthase kinase-3 alpha and -3 beta encoding genes. Genome 1998, 41:720-727.
220. Siderowf A., Stern M. Update on Parkinson disease. Ann. Intern. Med. 2003, 138:651-658.
221. Smeyne R.J., Jackson-Lewis V. The MPTP model of Parkinson's disease. Brain Res. Mol. Brain Res. 2005, 134:57-66.
222. Smith G.A., et al. Unilateral nigrostriatal 6-hydroxydopamine lesions in mice II: predicting l-DOPA-induced dyskinesia. Behav. Brain Res. 2012, 226:281-292.
223. Stocchi F., et al. Intravenous boluses and continuous infusions of L-dopa methyl ester in fluctuating patients with Parkinson's disease. Mov. Disord. 1992, 7:249-256.
224. Su P.C., et al. Subthalamotomy for advanced Parkinson disease. J. Neurosurg. 2002, 97:598-606.
225. Suarez J.I., et al. Pallidotomy for hemiballismus: efficacy and characteristics of neuronal activity. Ann. Neurol. 1997, 42:807-811.
226. Svenningsson P., et al. L-DOPA produces strong induction of c-fos messenger RNA in dopamine-denervated cortical and striatal areas of the common marmoset. Neuroscience 2000, 99:457-468.
227. Svenningsson P., et al. DARPP-32 mediates serotonergic neurotransmission in the forebrain. Proc. Natl. Acad. Sci. U. S. A. 2002, 99:3188-3193.
228. Tachibana Y., et al. Subthalamo-pallidal interactions underlying parkinsonian neuronal oscillations in the primate basal ganglia. Eur. J. Neurosci. 2011, 34:1470-1484.
229. Tamim M.K., et al. Effect of non-dopaminergic drug treatment on Levodopa induced dyskinesias in MPTP monkeys: common implication of striatal neuropeptides. Neuropharmacology 2010, 58:286-296.
230. Thomas A., et al. Duration of amantadine benefit on dyskinesia of severe Parkinson's disease. J. Neurol. Neurosurg. Psychiatry 2004, 75:141-143.
231. Togasaki D.M., et al. Levodopa induces dyskinesias in normal squirrel monkeys. Ann. Neurol. 2001, 50:254-257.
232. Ungerstedt U. 6-Hydroxy-dopamine induced degeneration of central monoamine neurons. Eur. J. Pharmacol. 1968, 5:107-110.
233. Ungerstedt U. Postsynaptic supersensitivity after 6-hydroxy-dopamine induced degeneration of the nigro-striatal dopamine system. Acta Physiol. Scand. Suppl. 1971, 367:69-93.
234. Ungerstedt U. 6-hydroxydopamine-induced degeneration of the nigrostriatal dopamine pathway: the turning syndrome. Pharmacol. Ther. B. 1976, 2:37-40.
235. Valjent E., et al. Regulation of a protein phosphatase cascade allows convergent dopamine and glutamate signals to activate ERK in the striatum. Proc. Natl. Acad. Sci. U. S. A. 2005, 102:491-496.
236. Valjent E., et al. Role of the ERK pathway in psychostimulant-induced locomotor sensitization. BMC Neurosci. 2006, 7:20.
237. Varanese S., et al. Treatment of advanced Parkinson's disease. Park. Dis. 2011, 2010:480260.
238. Velasco Suárez M.M., Escobedo F.R. Stereotaxic intracerebral instillation of dopa. Confin. Neurol. 1970, 32:149-157.
239. Vidailhet M., et al. The phenomenology of L-dopa-induced dyskinesias in Parkinson's disease. Mov. Disord. 1999, 14(Suppl. 1):13-18.
240. Walter B.L., Vitek J.L. Surgical treatment for Parkinson's disease. Lancet Neurol. 2004, 3:719-728.
241. Weinberger M., et al. Beta oscillatory activity in the subthalamic nucleus and its relation to dopaminergic response in Parkinson's disease. J. Neurophysiol. 2006, 96:3248-3256.
242. Wichmann T., et al. Comparison of MPTP-induced changes in spontaneous neuronal discharge in the internal pallidal segment and in the substantia nigra pars reticulata in primates. Exp. Brain Res. 1999, 125:397-409.
243. Winkler C., et al. L-DOPA-induced dyskinesia in the intrastriatal 6-hydroxydopamine model of parkinson's disease: relation to motor and cellular parameters of nigrostriatal function. Neurobiol. Dis. 2002, 10:165-186.
244. Xu Q., et al. Mouse models for LRRK2 Parkinson's disease. Parkinsonism Relat. Disord. 2012, 18(Suppl. 1):S186-S189.